How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in New Jersey

What NMN and NR actually are

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both small molecules that cells convert into nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in energy metabolism, DNA repair, and sirtuin signaling. They are not the same molecule and they are not interchangeable in regulatory terms. NR is the compound sold commercially as Niagen. NMN has no equivalent branded OTC product in the United States because of the FDA action described below. Neither is FDA-approved as a drug to treat, prevent, or cure any disease; any use for anti-aging or general wellness purposes is outside an FDA-approved indication.

In New Jersey, NR is available without a prescription. NMN is generally only available through a prescriber and a compounding pharmacy, which is why this page focuses on that access route.

Nicotinamide mononucleotide is not sold as an FDA-regulated dietary supplement in the United States because the FDA determined that NMN had already been authorized for investigation as a new drug (branded MIB-626) before it was marketed as a supplement (FDA, dietary supplements). Because of that, New Jersey patients who want a pharmacy-verified NMN product typically obtain it through a telehealth prescriber and a 503A compounding pharmacy rather than an OTC purchase. NR keeps its Generally Recognized as Safe status and remains available over the counter. Published human trials of both compounds have shown biomarker changes, such as rises in blood NAD+ or improved insulin sensitivity measures, over periods of six to ten weeks in small groups of specific populations (Yoshino et al., 2021; Martens et al., 2018), which is a different and much narrower evidence base than a proven long-term clinical benefit.

Why the FDA determination on NMN matters, and what it does not establish

The FDA's 2022 position is a marketing-status determination, not a safety finding against NMN and not an approval of any drug. It means NMN cannot be sold as a labeled dietary supplement ingredient because a company had already begun studying it as an investigational drug candidate (MIB-626) before it entered the supplement market. A randomized trial of MIB-626 in adults with overweight or obesity has reportedly shown measurable increases in circulating NMN and NAD+, but MIB-626 is a specific, patented pharmaceutical formulation being developed through the drug approval pathway. It is not the same product a compounding pharmacy dispenses under a prescription, and the existence of that drug trial does not mean compounded NMN has undergone equivalent testing or has FDA approval for any use. Readers should treat "FDA is studying an NMN drug" and "this pharmacy's compounded NMN capsule is FDA-reviewed" as two separate and unconnected facts. As of this writing, no oral NMN or NR product has FDA approval as a treatment for any condition; this status can change and should be checked against current FDA guidance before relying on it (dated claim, verify at fda.gov).

What the human trial evidence actually shows

The mechanistic case for NAD+ precursors rests on the fact that NAD+ levels decline with age and that restoring the precursor pool can raise NAD+ in blood and tissue. NMN and NR use different transporters into cells but converge on the same NAD+ synthesis pathway. A 2018 metabolic flux analysis of NAD+ synthesis and breakdown found that the NAD+ pool in human tissue turns over continuously rather than sitting as a fixed reserve, with production and consumption varying by tissue (Mendelsohn & Larrick's discussion is not cited here; see the primary flux analysis). That turnover model is one reason a single blood NAD+ measurement is hard to interpret in isolation: it reflects a moving balance, not a stored amount.

On the clinical side:

• A trial of oral NMN at 250 mg/day for 10 weeks in prediabetic postmenopausal women (n=25) found improved skeletal muscle insulin sensitivity (Yoshino et al., Science, 2021). This result applies to that specific population and duration; it does not establish an effect in men, in people without prediabetes, or over longer periods.
• A crossover trial of oral NR at 1,000 mg/day for 6 weeks in healthy adults aged 55 to 79 (n=24) found roughly a 60% rise in whole-blood NAD+ and a modest drop in systolic blood pressure, and reported the supplement was well tolerated (Martens et al., Nature Communications, 2018).
• A review of preclinical and early clinical NAD+ precursor studies concluded that the body of work consistently shows increases in NAD+ metabolites in blood and tissue, while noting that data on long-term clinical outcomes remain limited (Reiten et al., GeroScience, 2021).
• Preclinical work in aged mice found that long-term NMN administration improved several markers of metabolic and physiological decline, including liver-related measures (Mills et al., Cell Metabolism, 2016). This is animal data and should not be read as evidence of a hepatoprotective effect in humans.
• NR's oral bioavailability in humans and mice was established in an early pharmacokinetic study (Trammell et al., Nature Communications, 2016).

Most of the disease-specific research on NAD+ precursors involves animal models of particular conditions rather than healthy human aging. A 2024 study, for example, found that NAD+ precursor administration prolonged survival and improved cardiac measures in a mouse model of Friedreich's ataxia, a specific inherited neuromuscular disease (Cortopassi lab, 2024). That finding does not establish an effect in humans with Friedreich's ataxia, and it says nothing about outcomes in people without the disease who take NMN or NR for general longevity purposes. It shows how far current preclinical research has moved from the general healthy-aging claims often used to market these compounds.

Evidence boundary map: what is established, what is plausible, what is not established

How telehealth prescribing works in New Jersey

New Jersey allows licensed prescribers to evaluate a patient and issue a prescription through a synchronous audio-video telehealth visit without a required prior in-person visit, under the state's telemedicine statute (verify the current citation and any amendments at njleg.state.nj.us). This generally covers prescriptions for compounded NMN or NR.

A typical workflow: the patient completes an intake form covering health history and current medications, labs are ordered or reviewed, a live video visit occurs, and if the provider determines the patient is appropriate, a prescription is sent to a 503A compounding pharmacy. The provider does not need a physical New Jersey office but does need an active New Jersey license, or a license recognized through an interstate arrangement such as the Interstate Medical Licensure Compact, of which New Jersey is a participating state (confirm current member status at imlcc.org, since compact membership and rules can change).

Total time from intake to a filled prescription depends mainly on lab turnaround and pharmacy processing rather than the telehealth visit itself, and will vary by platform and pharmacy.

Who can prescribe NMN or NR in New Jersey

Three provider types can prescribe in New Jersey, with different scopes of authority:

• Physicians (MD/DO) have unrestricted prescriptive authority and can prescribe compounded NMN or NR without a collaborative agreement requirement.
• Nurse practitioners in New Jersey gained expanded independent prescribing authority through state legislation effective in 2022. The exact statutory citation, any hour or protocol requirements, and current scope should be confirmed against the NJ Board of Nursing or njleg.state.nj.us, since this is a relatively recent change and details are easy to misstate.
• Physician assistants generally prescribe under a collaborative agreement with a supervising physician, who must have authorized NAD precursors within the PA's delegated prescriptive scope.

Labs commonly used before starting

Clinicians who prescribe NAD precursors commonly order baseline labs, though exact panels vary by practice and none of the specific numeric thresholds below should be read as a diagnostic rule for an individual reader; a specific cutoff for starting therapy is a clinical judgment call made by the prescriber, not a fixed lab number:

• Metabolic markers: fasting glucose, HbA1c, fasting insulin, and a comprehensive metabolic panel. Insulin resistance measures (such as HOMA-IR) were used as an inclusion criterion in the Yoshino NMN trial, but the specific cutoff used in that trial should be verified against the original paper rather than assumed for clinical use.
• NAD-related biomarkers: some longevity practices order whole-blood NAD+ testing through specialty labs. This is not a standardized or universally required test, and a specific numeric threshold for "low" NAD+ that should trigger supplementation is not established in the literature reviewed for this article.
• Hepatic function: AST, ALT, and GGT, to screen for active liver disease before starting an oral compound metabolized through the liver. Note that hepatoprotective findings for NMN come from mouse studies, not human liver-safety data.
• Inflammatory markers: hsCRP and sometimes IL-6, used by some practices to stratify patients, though this is not a standard requirement.

Labs can generally be drawn at commercial labs such as Quest Diagnostics or LabCorp in New Jersey, and some telehealth platforms offer at-home phlebotomy. Turnaround time varies by lab and test.

503A compounding pharmacies and shipping

A 503A compounding pharmacy prepares a medication for an individual patient under a valid prescription, subject to state board of pharmacy licensing and USP compounding standards. New Jersey's Board of Pharmacy licenses and inspects 503A pharmacies operating in the state (NJ Division of Consumer Affairs, Board of Pharmacy). Patients can fill prescriptions at an in-state 503A pharmacy or at an out-of-state 503A pharmacy holding a New Jersey non-resident pharmacy license.

Compounded NMN is typically prepared as an oral capsule; some compounders also offer sublingual formulations intended to bypass first-pass liver metabolism. Compounded NR capsules exist but are less common since the commercial Niagen product remains available OTC. Storage stability and shelf life vary by formulation and pharmacy; check the specific product label rather than assuming a fixed shelf life, since this is not standardized across compounders.

Neither NMN nor NR is a federally or New Jersey scheduled controlled substance, so the additional transfer restrictions that apply to controlled substances do not apply here.

NJ Medicaid, prior authorization, and cash pricing: what is verified and what is not

General Medicaid programs, including NJ FamilyCare, commonly require prior authorization for compounded products that lack an FDA-approved commercial equivalent, and it is reasonable to expect that a compounded NAD precursor would fall into that administrative category. However, none of the specific operational details, which pharmacy benefit administrator handles the request, what documentation is required, how long approval takes, or what percentage of requests are approved, could be verified from primary sources for this article. Readers should not treat any specific turnaround time or approval rate as fact unless they get it in writing from NJ FamilyCare or the prescribing clinic's billing staff, since these details are administrative and can change without notice.

The same caution applies to cash pricing. Compounded product prices vary by pharmacy, dose, and formulation, and no specific dollar figure could be confirmed from the sources used here. Ask the dispensing pharmacy for a written price quote before committing to a prescription, and ask your commercial insurer directly whether compounded, non-FDA-approved NAD precursors are covered under your specific plan; most commercial plans historically have not covered compounded longevity products, but plan design changes over time and by employer.

Transferring an existing NMN or NR prescription into New Jersey

An active NMN or NR prescription can generally be transferred to a New Jersey-licensed pharmacy under standard state pharmacy transfer rules, with the receiving pharmacy contacting the originating pharmacy to verify details. If the original prescriber is not licensed in New Jersey, the transferred prescription typically remains valid for its current fill and any remaining authorized refills, but a New Jersey-licensed (or compact-licensed) prescriber will be needed for any new prescription once those refills are used. Because neither compound is a controlled substance, the extra transfer restrictions that apply to scheduled drugs do not apply.

Monitoring after starting NMN or NR

Prescribers commonly recommend follow-up labs some weeks after starting an NAD precursor, though the specific interval is a clinical judgment rather than a fixed rule; the Martens NR trial measured its NAD+ increase at six weeks, which is a common reference point some practices use for timing a first follow-up check.

In the trials reviewed here, reported side effects were generally mild and included flushing (reported in a portion of NR recipients at 1,000 mg/day), transient nausea, and mild headache. No serious adverse events attributable to NMN or NR were reported in these specific trials, but these were short studies (weeks, not years) in relatively small, often healthy populations, so long-term safety data are limited and should not be assumed to be comprehensive.

Tell your prescriber about all other medications and supplements. No clinically established drug interaction has been documented for NMN or NR in the sources reviewed here, but high-dose niacin (vitamin B3) shares overlapping NAD biosynthesis pathways and could theoretically add to flushing symptoms; this is a plausible, not confirmed, interaction and is worth mentioning to a prescriber rather than something to self-manage.

When to seek urgent or same-day medical care: stop the product and contact your prescriber or seek urgent evaluation if you develop signs suggestive of liver injury (yellowing of skin or eyes, dark urine, right upper abdominal pain), a severe allergic reaction, chest pain, or any other severe or rapidly worsening symptom after starting a new compounded product. This article does not provide individualized dosing or diagnostic guidance; those decisions belong to your prescriber based on your specific history and labs.

Verification checklist: stable facts vs. facts you must confirm yourself

Use this before relying on anything a telehealth platform, pharmacy, or ad tells you about NMN/NR access in New Jersey.

Generally stable, checkable against federal or clinical sources (lower risk of being out of date):

• NMN cannot currently be sold as a labeled OTC dietary supplement in the US (confirm at fda.gov/food/dietary-supplements)
• NR retains GRAS status (confirm at FDA GRAS notice inventory)
• Neither NMN nor NR is a federally scheduled controlled substance
• The published human trials cited for NMN/NR (Yoshino 2021, Martens 2018) studied specific, narrow populations over weeks, not years
• Neither compound is FDA-approved to treat, prevent, or cure any disease

Date sensitive, must be verified directly before you rely on it or pay money:

• The exact New Jersey telemedicine statute citation and any recent amendments (njleg.state.nj.us)
• Current New Jersey nurse practitioner independent prescribing rules and any protocol requirements (NJ Board of Nursing)
• Whether New Jersey is still an active Interstate Medical Licensure Compact member and current compact rules (imlcc.org)
• Whether the specific compounding pharmacy is currently licensed in New Jersey or holds a valid non-resident license (NJ Board of Pharmacy)
• NJ FamilyCare's current prior authorization criteria, documentation requirements, and processing timelines for compounded, non-FDA-approved products (ask NJ FamilyCare or your plan directly)
• Your own commercial plan's coverage stance on compounded NAD precursors (call your insurer)
• Current cash price, dose strength, and formulation from the specific dispensing pharmacy (get a written quote)
• Current shipping and processing timelines from the specific pharmacy you plan to use

The core answer sits at the intersection of these two lists: New Jersey's legal and clinical framework for accessing NMN/NR through telehealth and compounding is well established, but the money and coverage details that most affect a patient's actual experience are the parts most likely to be wrong if copied from a generic web page instead of confirmed directly on the date of use.

Delivery note for editorial and medical review: the source draft contained a long quotation attributed to a named trial author and a separate quotation attributed to a named researcher on telehealth prescribing patterns; neither could be verified against a citable source and both have been removed and converted to attributed paraphrase or omitted. The source also stated specific NJ Medicaid prior authorization criteria, a named pharmacy benefit administrator, specific approval turnaround times, and specific cash price ranges with no supporting citation; these have been flagged as unverified rather than presented as fact, per the evidence rules for this draft. A reference to a JAMA Network Open statistic (31% of tested products underdosed) linked only to the journal's homepage rather than a specific article and has been removed rather than presented as a sourced figure. This article requires qualified medical and legal review before publication, particularly the New Jersey licensure, Medicaid, and pricing sections.